SURF: Announcements of Opportunity
Below are Announcements of Opportunity posted by Caltech faculty and JPL technical staff for the SURF program. Additional AOs for the Amgen Scholars program can be found here.
Specific GROWTH projects being offerred for summer 2018 can be found here.
Each AO indicates whether or not it is open to non-Caltech students. If an AO is NOT open to non-Caltech students, please DO NOT contact the mentor.
Announcements of Opportunity are posted as they are received. Please check back regularly for new AO submissions! Remember: This is just one way that you can go about identifying a suitable project and/or mentor.
Announcements for external summer programs are listed here.
Students pursuing opportunities at JPL must be
U.S. citizens or U.S. permanent residents.
|Project:||Development of Metabolically Viable and Replication Incompetent Vaccines|
|Disciplines:||Biology, Microbiology, Immunology|
Prof. of Microbiology, Immunology, and Pathology, (BBE),
|Mentor URL:||http://www.cvmbs.colostate.edu/DirectorySearch/Search/MemberProfile/cvmbs/38341/Goodrich/Raymond (opens in new window)|
NOTE: This project is being offered by a Caltech alumnus and will be conducted at Colorado State University in Fort Collins, Colorado.
This project is focused on using a novel method for generating replication incompetent but metabolically viable vaccine candidates for infectious diseases. The initial focus is on the use of Mycobacteria spp. for use in vaccination strategies against Tuberculosis infections. The studies will involve both in vitro and animal challenge studies with vaccine candidates created in the research program.
|Description:||The student will be involved in culturing of bacterial strains ranging from BSL1 to BSL3, characterization of agents treated with a photochemical process used to generate specific genetic lesions which render the organisms incapable of replication. These methods will include NMR, HPLC and Mass Spectroscopy.|
1. Plotkin SA, Plotkin SL (2011) The development of vaccines: How the past led to the future. Nat Rev Microbiol 9(12):889–893.
2. Queenan AM, Cassiday PK, Evangelista A (2013) Pertactin-negative variants of Bordetella
pertussis in the United States. N Engl J Med 368(6):583–584.
3. Lipsitch M, O’Hagan JJ (2007) Patterns of antigenic diversity and the mechanisms that
maintain them. J R Soc Interface 4(16):787–802.
4. ??towska M, Przybylska Z, Piotrowski D, Lachert E, Rosiek A, Rzymkiewicz L, Cardoso M (2016) Hemovigilance survey of pathogen-reduced blood components in the Warsaw Region in the 2009 to 2013 period.Transfusion 56 Suppl 1:S39-44.
5. Kumar, V., Lockerbie, O., Keil, S., Ruane, P., Platz, M., Martin, C., Ravanat, J., Cadet, J., Goodrich, R. (2004). Riboflavin and UV-Light Based Pathogen Reduction: Extent and Consequence of DNA Damage at the Molecular Level. Photochemistry and Photobiology; 80: 15-21.
6. Goodrich, R. P., Edrich, R. A., Goodrich, L. L, Scott, C. A., Manica, K.J., Hlavinka, D. J., Hovenga, D. H., Hansen, E. T., Gampp, D., Keil, S. D., Gilmour, D. I., Li, J., Martin, C. B., and Platz, M. S. (2006). The Antiviral and Antibacterial Properties of Riboflavin and Light: Applications to Blood Safety and Transfusion Medicine. Comprehensive Series in Photochemistry and Photobiology-Volume 6; Flavins: Photochemistry and Photobiology. Royal Society of Chemistry; Cambridge, UK. E. Silva and A. M. Edwards, editors.
7. JM Mundt, L Rouse, J Van den Bossche, RP Goodrich (2014) Chemical and Biological Mechanisms of Pathogen Reduction Technologies. Photochemistry and Photobiology 90 (5), 957-964
8. Raymond P. Goodrich, Krishna K. Murthy, Suzann K. Doane, Christy N. Fitzpatrick, La Shayla Morrow, Patricia A. Arndt, Heather L. Reddy, Kimberley A. Buytaert-Hoefen, and George Garratty (2008) Evaluation of Potential Immune Response and In Vivo Survival of Riboflavin-Ultraviolet Light–Treated Red Blood Cells in Baboons. Transfusion. 49: 69-74.
9. Martin, C. B., Wilfong, E., Ruane, P., Goodrich, R., and Platz, M. (2004) An Action Spectrum of the Riboflavin Photosensitized Inactivation of Lambda Phage. Photochemistry and Photobiology, 81: 474-480.
10. SD Keil, N Hovenga, D Gilmour, S Marschner, R. Goodrich (2015) Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination; J Vis Exp.; (102): 52820. Published online 2015 Aug 24. doi: 10.3791/52820.
11. Keil,S. D., Bengrine, A., Bowen, R., Marschner, S. , Hovenga, N., Rouse, L., Gilmour., D., Duverlie,G. and Goodrich, R.P. (2014) Inactivation of Viruses in Platelet and Plasma Products using a Riboflavin and UV based Photochemical Treatment; Transfusion, 55(7):1736-44.
12. Fast, L.D., DiLeone, G., Li, J. and Goodrich, R. (2006) Functional Inactivation of White Blood Cells by Mirasol Treatment. Transfusion, 46: 642-648.
13. Callahan SM, Wonganan P, Obenauer-Kutner LJ, Sutjipto S, Dekker JD, Croyle MA (2008)
Controlled inactivation of recombinant viruses with vitamin B2. J Virol Methods 148(1-2):132-45.
14. Reddy, H., Dayan, A. D., Cavagnaro, J, Gad, S., Li, J., and Goodrich, R. (2008) Toxicity Testing of the Mirasol PRT Process for Platelets and Plasma: A Novel Riboflavin-Based Pathogen Reduction Technology for Blood Transfusion Safety. Transfusion Medicine Reviews. 22(2): 133-153.
|Student Requirements:||Microbiology, Immunology, Pathology or related fields. Training in laboratory procedures with BSL2-3 level agents would be preferred.|
This AO can be done under the following programs:
<< Prev Record 13 of 112 Next >> Back To List